Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 6/20 | 0.49 |
| ▸ | NPC1 | O15118 | 4/20 | 0.49 |
| ▸ | GFER | P55789 | 1/20 | 0.49 |
| ▸ | FBP1 | P09467 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | STAT1 | P42224 | 1/20 | 0.44 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.44 |
| ▸ | F2RL3 | Q96RI0 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3822917 | 0.87 | SMN1; SMN2 (0.48) | L3MBTL1GAARAB9ANPC1GFER | |
| SCHEMBL7988985 | 0.84 | L3MBTL1 (0.51) | L3MBTL1GAARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL12186363 | 0.83 | L3MBTL1 (0.47) | L3MBTL1GAARAB9ANPC1GFER | |
| SCHEMBL16362493 | 0.83 | L3MBTL1 (0.47) | L3MBTL1GAARAB9ANPC1GFER | |
| SCHEMBL2706413 | 0.81 | NPC1 (0.49) | RAB9ANPC1GFERFBP1TRPV1 | |
| SCHEMBL18090844 | 0.81 | L3MBTL1 (0.49) | L3MBTL1GAARAB9ANPC1GFER | |
| SCHEMBL19102836 | 0.80 | L3MBTL1 (0.45) | L3MBTL1GAARAB9ANPC1GFER | |
| SCHEMBL23095285 | 0.80 | NPC1 (0.48) | RAB9ANPC1GFERFBP1TRPV1 | |
| SCHEMBL3068277 | 0.80 | FBP1 (0.50) | GAARAB9ANPC1GFERFBP1 | |
| SCHEMBL179531 | 0.80 | MAPT (0.56) | GAARAB9ANPC1GFERFBP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024137548-A2 | INHIBITORS OF JAK2 | Llydaw Therapeutics, Inc. (US) | 2024-06-27 | — | — | WO | disclosed |
| US-12016852-B2 | Pyrrolidine glycosidase inhibitors | ASCENEURON SA (CH) | 2024-06-25 | — | — | US | disclosed |
| US-11858937-B2 | Substituted pyrazolo[1,5-a]pyrimidines and pyrazolo[1,5-a][1,3,5]triazines as CDK inhibitors | QURIENT CO., LTD. (KR) | 2024-01-02 | — | — | US | disclosed |
| US-11795165-B2 | Tetrahydro-benzoazepine glycosidase inhibitors | ASCENEURON SA (CH) | 2023-10-24 | — | — | US | disclosed |
| US-11795165-B2 | Tetrahydro-benzoazepine glycosidase inhibitors | ASCENEURON SA (CH) | 2023-10-24 | — | — | US | disclosed |
| US-11731972-B2 | Spiro compounds as glycosidase inhibitors | ASCENEURON SA (CH) | 2023-08-22 | — | — | US | disclosed |
| US-11731972-B2 | Spiro compounds as glycosidase inhibitors | ASCENEURON SA (CH) | 2023-08-22 | — | — | US | disclosed |
| US-20230212183-A9 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2023-07-06 | — | — | US | disclosed |
| US-20230142839-A1 | N4-phenyl-quinazoline-4 -amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases | ARRAY BIOPHARMA INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230145071-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION | 2023-05-11 | — | — | US | disclosed |
| US-7411072-B2 | Tricyclic steroid hormone nuclear receptor modulators | ELI LILLY AND COMPANY (US) | 2008-08-12 | — | — | US | disclosed |
| US-7411072-B2 | Tricyclic steroid hormone nuclear receptor modulators | ELI LILLY AND COMPANY (US) | 2008-08-12 | — | — | US | disclosed |
| US-20070213333-A1 | Substituted arylalkanoic acid derivatives and use thereof | ASAHI KASEI PHAMA CORPORATION (JP) | 2007-09-13 | — | — | US | disclosed |
| US-7262318-B2 | Substituted heteroaryl- and phenylsulfamoyl compounds | PFIZER, INC. (US) | 2007-08-28 | — | — | US | disclosed |
| WO-2007061768-A2 | FLUORESCENT MEMBRANE INTERCALATING PROBES AND METHODS FOR THEIR USE | PHANOS TECHNOLOGIES, INC. (US) | 2007-05-31 | — | — | WO | disclosed |
| WO-2007061768-A2 | FLUORESCENT MEMBRANE INTERCALATING PROBES AND METHODS FOR THEIR USE | PHANOS TECHNOLOGIES, INC. (US) | 2007-05-31 | — | — | WO | disclosed |
| US-20070072898-A1 | Pyrazolo[1,5-a]pyridine derivatives or pharmaceutically acceptable salts thereof | TEIJIN PHARMA LIMITED | 2007-03-29 | — | — | US | disclosed |
| US-7169817-B2 | Bis-aromatic alkanols | IRM LLC (BM) | 2007-01-30 | — | — | US | disclosed |
| US-7169817-B2 | Bis-aromatic alkanols | IRM LLC (BM) | 2007-01-30 | — | — | US | disclosed |
| US-4594426-A | Benzoxazole derivative intermediates for synthesis of dye releasing redox compounds | FUJI PHOTO FILM CO., LTD. (JP) | 1986-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072898-A1 | Pyrazolo[1,5-a]pyridine derivatives or pharmaceutically acceptable salts thereof | MAPKAPK2, MAP4K2, MAPKAPK5 | L3MBTL1 4353/4885GAA 4411/4885RAB9A 1024/4885 |
| US-11858937-B2 | Substituted pyrazolo[1,5-a]pyrimidines and pyrazolo[1,5-a][1,3,5]triazines as CDK inhibitors | CDKL5, CDK15, CDK5 | L3MBTL1 3644/4885GAA 2264/4885RAB9A 3277/4885 |
| US-20230145071-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | L3MBTL1 2548/4885GAA 1534/4885RAB9A 2092/4885 |
| US-12016852-B2 | Pyrrolidine glycosidase inhibitors | PREP, GAA, DNPEP | L3MBTL1 764/4885GAA 2/4885RAB9A 1240/4885 |
| US-20230142839-A1 | N4-phenyl-quinazoline-4 -amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases | ERBB4, ERBB2, ERBB3 | L3MBTL1 1535/4885GAA 2375/4885RAB9A 1344/4885 |
| US-20230212183-A9 | INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | L3MBTL1 424/4885GAA 2064/4885RAB9A 33/4885 |
| US-11731972-B2 | Spiro compounds as glycosidase inhibitors | GLA, BACE1, GAA | L3MBTL1 2554/4885GAA 3/4885RAB9A 983/4885 |
| US-20070213333-A1 | Substituted arylalkanoic acid derivatives and use thereof | CYSLTR1, CYSLTR2, LTB4R2 | L3MBTL1 3073/4885GAA 2785/4885RAB9A 2601/4885 |
| US-11795165-B2 | Tetrahydro-benzoazepine glycosidase inhibitors | BACE1, BACE2, BCHE | L3MBTL1 202/4885GAA 6/4885RAB9A 2306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.